Ultragenyx Pharmaceutical Inc. Files 8-K

TL;DR

UGNX filed an 8-K on Feb 13, 2025, reporting on financials. No numbers yet.

AI Summary

On February 13, 2025, Ultragenyx Pharmaceutical Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were disclosed in the provided excerpt.

Why It Matters

This 8-K filing indicates that Ultragenyx Pharmaceutical Inc. is providing updates on its financial condition and operational results to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report for operational and financial updates, with no immediate negative or positive indicators in the provided text.

Key Players & Entities

• Ultragenyx Pharmaceutical Inc. (company) — Registrant
• February 13, 2025 (date) — Date of earliest event reported
• 60 Leveroni Court, Novato, California 94949 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value RARE Nasdaq Global Select

Filing Documents

• rare-20250213.htm (8-K) — 46KB
• rare-ex99_1.htm (EX-99.1) — 377KB
• img45776771_0.jpg (GRAPHIC) — 24KB
• img45776771_1.jpg (GRAPHIC) — 24KB
• 0000950170-25-019854.txt ( ) — 616KB
• rare-20250213.xsd (EX-101.SCH) — 23KB
• rare-20250213_htm.xml (XML) — 4KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 13, 2025, Ultragenyx Pharmaceutical Inc. issued a press release announcing its financial results for the three months ended December 31, 2024 and for the year ended December 31, 2024 (the " Press Release "). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated February 13, 2025. 104 The cover page from the Company's Current Report on Form 8-K dated February 13, 2025 formatted in Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ultragenyx, Pharmaceutical, Inc. Date: February 13, 2025 By: /s/ Howard Horn Executive Vice President, Chief Financial Officer, Corporate Strategy

View Full Filing

View this 8-K filing on SEC EDGAR